### **VERSION HISTORY**

V1	05/12/202	Internal development
----	-----------	----------------------

#### **PROTOCOL**

This document contains the outcome specific elements necessary to implement this protocol: <a href="mailto:post-covid-events.docx">post-covid-events.docx</a>

# **STUDY POPULATION**

No additional criteria.

## **OUTCOMES**

Subcategory	Event	Codelists	
Arterial thrombosis	A suite reve condict information	SNOMED	
events	Acute myocardial infarction	<u>ICD-10</u>	
Arterial thrombosis	Ischaemic stroke	SNOMED	
events	Ischaemic shoke	<u>ICD-10</u>	
Venous		SNOMED	
thromboembolism events	Pulmonary embolism	<u>ICD-10</u>	
.,,		SNOMED	
Venous thromboembolism	Deep vein thrombosis (including	SNOMED	
events	during pregnancy)	<u>ICD-10</u>	
		<u>ICD-10</u>	
Other cardiovascular	Transient ischaemic attack	SNOMED	
events	Transient isenaemie attack	<u>ICD-10</u>	
Other cardiovascular	Subarachnoid haemorrhage and haemorrhagic stroke	SNOMED	
events		<u>ICD-10</u>	
Other cardiovascular	Heart failure	SNOMED	
events		ICD-10	
Other cardiovascular	Angina	SNOMED	
events	1g	ICD-10	
		AMI - <u>SNOMED</u>	
	Arterial thrombosis events (i.e., any of acute myocardial infarction, ischaemic stroke, and other arterial embolism)	Ischaemic stroke - SNOMED	
Arterial thrombosis		Other arterial embolism – <u>SNOMED</u>	
events		AMI - <u>ICD-10</u>	
		Ischaemic stroke - ICD-10	
		Other arterial embolism – <u>ICD-10</u>	
	Venous thromboembolism events (i.e., any of portal vein thrombosis,	PE - <u>SNOMED</u>	
Venous		DVT - <u>SNOMED</u>	
thromboembolism	deep vein thrombosis (including during pregnancy), intracranial	DVT pregnancy - <u>SNOMED</u>	
events	venous thrombosis, other deep	Other DVT - SNOMED	
	vein thrombosis, and pulmonary	ICVT - <u>SNOMED</u>	

embolism)	Portal vein thrombosis – <u>SNOMED</u>
	PE - <u>ICD-10</u>
	DVT - <u>ICD-10</u>
	DVT pregnancy - <u>ICD-10</u>
	Other DVT - ICD-10
	ICVT - <u>ICD-10</u>
	ICVT pregnancy - ICD-10
	Portal vein thrombosis - ICD-10

# **POTENTIAL CONFOUNDERS**

We will consider the following potential confounders, which will be defined using the most recent data prior to the study start date:

Confounder	Туре	Definition	Data sources
Sex*	Categorical	Male, Female	Primary care (see: https://docs.opensafely.or g/study-def- variables/#cohortextractor. patients.sex)
Age	Continuous	Modelled as age in years using a restricted cubic spline with 3 knots at the 10 <sup>th</sup> , 50 <sup>th</sup> and 90 <sup>th</sup> percentiles	All
Ethnicity	Categorical	1: White 2: Mixed 3: South Asian 4: Black 5: Other 6: Missing	All
Deprivation	Categorical	Index of Multiple Deprivation 2019 quintiles	Index of Multiple Deprivation 2019
Region	Categorical	East East Midlands London North East North West South East South West West Midlands Yorkshire/Humber	Primary care
Patient-GP contact	Continuous	Number of primary care contacts in the year prior to index date	Primary care
Smoking status	Categorial	E: Ex smoker M: Missing N: Never smoker S: Current smoker	Primary care
Obesity	Binary	1 if BMI>=30 or coded diagnosis	Primary care, HES APC

		for obesity; 0 otherwise	
Acute myocardial infarction	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
All stroke	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Other arterial embolism	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Venous thromboemboli sm events	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Heart failure	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Angina	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Dementia	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Liver disease	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Chronic kidney disease	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Cancer	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Hypertension	Binary	1 if diagnosis or prescription present; 0 otherwise	Primary care, HES APC
Diabetes	Binary	1 if diagnosis or prescription present; 0 otherwise	Primary care, HES APC
Depression	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Chronic obstructive pulmonary disease	Binary	1 if diagnosis present; 0 otherwise	Primary care, HES APC
Lipid lowering medications	Binary	1 if prescription present; 0 otherwise	Primary care
Antiplatelet medications	Binary	1 if prescription present; 0 otherwise	Primary care
Anticoagulatio n medications	Binary	1 if prescription present; 0 otherwise	Primary care
Combined oral contraceptive pill	Binary	1 if prescription present; 0 otherwise	Primary care
Hormone replacement therapy	Binary	1 if prescription present; 0 otherwise	Primary care
Healthcare worker*	Binary	1 if healthcare worker; 0 otherwise	NHS England COVID-19 data store (see: https://docs.opensafely.or g/study-def- variables/#cohortextractor. patients.with_healthcare_ worker_flag_on_covid_vac cine_record)

Care home resident	Binary	1 if care home resident; 0 otherwise	Address matching CQC database (see: https://docs.opensafely.or g/study-def-variables/#cohortextractor. patients.care_home_statu s_as_of)
--------------------	--------	--------------------------------------	--

<sup>\*</sup> These variables are derived once per patient without a data specification so are an exception to 'most recent data prior to the study start date'

#### PROPOSED OUTPUTS

The proposed outputs from this protocol will be like those included in the paper 'Association of COVID-19 with arterial and venous vascular diseases: a population-wide cohort study of 48 million adults in England and Wales'. Listed here for convenience:

Table 1. Number of patients analysed and, in paratheses, the risk per 100,000 of hospitalized and non-hospitalized SARS-CoV-2 infection

Table 2. Numbers of arterial thrombotic, venous thromboembolic and other vascular events before and after SARS-CoV-2 infection

Figure 1. Hazard ratios (log scale) for different arterial thrombotic, and venous thromboembolic and other vascular events after SARS-CoV-2 infection by time since diagnosis.

Figure 2. Hazard ratios (log scale) for arterial thrombotic events after SARS-CoV-2 infection by time since diagnosis, overall and stratified by whether hospitalised with SARS-CoV-2 infection, prior history of an arterial event, age, sex and ethnicity.

Figure 3. Hazard ratios (log scale) for venous thromboembolic events after SARS-CoV-2 infection by time since diagnosis, overall and stratified by whether hospitalised with SARS-CoV-2 infection, prior history of an arterial event, age, sex and ethnicity.

Figure 4. Absolute increase in risk of arterial thrombotic and venous thromboembolic events over time after SARS-CoV-2 infection, compared with no SARS-CoV-2 infection.

Supplementary Table 1. Derivation of major outcomes in OpenSafely.

Supplementary Table 2. Derivation of covariates.

Supplementary Table 3. Hazard ratios compared with no SARS-CoV-2 infection, according to time since SARS-CoV-2 infection. All results are maximally adjusted unless otherwise stated.

Supplementary Figure 1. Hazard ratios (log scale) for different after SARS-CoV-2 infection by time since diagnosis, stratified by where hospitalised with SARS-CoV-2 infection.

Supplementary Figure 2. Increases in absolute risk of arterial (upper plots) and venous events (lower plots) by time since diagnosis.